Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOther Non Operating IncomeProfit After TaxRent ExpenseResearch & DevelopmentSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Alterity Therapeutics (ATHE) EPS (Weighted Average and Diluted) (2016 - 2019)

Alterity Therapeutics' quarterly EPS (Weighted Average and Diluted) came in at -$8.68 in Q4 2019, down 151.86% year-on-year from $16.73 in Q4 2018, and down 151.86% quarter-over-quarter from -$3.45 in Q4 2018.

Alterity Therapeutics has reported EPS (Weighted Average and Diluted) for 4 years, with the latest figure at -$8.68 in Q4 2019.

  • For the quarter ending Q4 2019, EPS (Weighted Average and Diluted) fell 151.86% year-over-year to -$8.68; the trailing twelve-month figure through Jun 2021 stood at -$0.0 (up 77.49% YoY), and the FY2025 full-year result was -$0.12, up 64.49% from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2019 stood at -$8.68, down from -$3.45 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was -$2.52 in Q4 2016, with the low at -$8.68 in Q4 2019.
  • Average EPS (Weighted Average and Diluted) over 4 years is -$4.3, with a median of -$3.01 recorded in 2017.
  • Year-over-year, EPS (Weighted Average and Diluted) declined 1.87% in 2017 and plunged 151.86% in 2019.
  • Tracing ATHE's EPS (Weighted Average and Diluted) over 4 years: stood at -$2.52 in 2016, then fell by 1.87% to -$2.57 in 2017, then sank by 34.29% to -$3.45 in 2018, then sank by 151.86% to -$8.68 in 2019.
  • The last three EPS (Weighted Average and Diluted) figures came in at -$8.68 (Q4 2019), -$3.45 (Q4 2018), and -$2.57 (Q4 2017), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EPS (Weighted Avg. Diluted) (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -4.43
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 3,086.42
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 0.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 4.02
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 6.75
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 1.51
10 Revolution Medicines 32.39 Bn 32.39 Bn - -2.29

Historic Data

Download Data 🔒
DateValue
Dec 31, 2019 -8.68
Dec 31, 2018 -3.45
Dec 31, 2017 -2.57
Dec 31, 2016 -2.52